With the buzz around Ozempic and other GLP-1 medications showing no sign of dying down, the impact of interest and usage will continue to be felt across all industries.
For the innovator, the primary data questions are: Who has filed a P.IV against my products? What are the weak patents in my thicket? What is the patent cliff exposure of my M&A target, and how does it affect the deals NPV? For the generic and biosimilar challenger, the primary questions are: Which high-value products have thin or weak patent estates? Can we be first to file a P.IV? What API suppliers are qualified and available for our target drugs active ingredient? For institutional investors, the questions are: What is the aggregate LOE exposure in this companys commercial portfolio over the next 5 years? Is the market correctly pricing the risk that a P.IV challenge will succeed and generate an early generic? What does the biosimilar pipeline look like for the top five drugs in this Big Pharmas revenue mix? The CI Playbook for Each Market Participant Competitive intelligence in pharmaceutical patent strategy is not a single discipline it is a set of distinct analytical functions tailored to the decision-making context of each player in the LOE ecosystem
El LXR interacciona con el PPAR- de una manera recprocamente inhibitoria, de modo que los 2 receptores ejercen funciones opuestas sobre el metabolismo lipdico
CoolSculpting has several different applicator devices, each designed for specific body areas
Another nonrandomized study also suggests that a homocysteine-lowering treatment would decrease the risk of atherothrombotic disease (Peterson and Spence, 1998)
)
